Publication:
Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?

Simple item page
dc.contributor.coauthorKanbay, Asiye
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileResearcher
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteGraduate School of Health Sciences
dc.contributor.yokid110580
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T13:10:02Z
dc.date.issued2022
dc.description.abstractPatients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of coronavirus disease 2019 (COVID-19)-related death. Renin-angiotensin-aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the pre-clinical demonstration of COVID-19 viral entry into cells via angiotensin-converting enzyme-2, the use of RAS blockers was questioned in infected individuals. Theodorakopoulou et al. extensively review the pathophysiology behind that hypothesis and observational or clinical trials on RAS blockers and COVID-19. Despite being a scientific hot spot of an ongoing debate, discontinuation of RAS blockers is not associated with improved clinical outcomes in COVID-19 and may have potential harmful effects, including exacerbation of the underlying disease.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume15
dc.formatpdf
dc.identifier.doi10.1093/ckj/sfac001
dc.identifier.eissn2048-8513
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03569
dc.identifier.issn2048-8505
dc.identifier.linkhttps://doi.org/10.1093/ckj/sfac001
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85142656124
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2790
dc.identifier.wos769662400001
dc.keywordsChronic kidney disease
dc.keywordsCOVID-19
dc.keywordsHypertension
dc.keywordsRenin angiotensin system
dc.languageEnglish
dc.publisherOxford University Press (OUP)
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10429
dc.sourceClinical Kidney Journal
dc.subjectUrology and nephrology
dc.titleShould we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?
dc.typeOther
dc.type.otherEditorial material
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.authoridN/A
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10429.pdf
Size:
176.1 KB
Format:
Adobe Portable Document Format
Download

Collections

Publications with Fulltext